RVPH — REVIVA PHARMACEUTICALS HOLDINGS, INC.
—
OTC ·
Health Care ·
Pharmaceuticals ·
CIK 1742927 ·
Last close
$0.31
Market Cap
$4.02M
52W High
$15.40
52W Low
$0.26
ADV30
33,522
Next earnings
2026-11-16
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -2,432,518 | -2,298,905 | 18,557,325 | 17,458,418 | 5,477,964 |
| Jun 2026 | 0 | — | -2,617,543 | -2,447,831 | 21,140,590 | 19,889,960 | 5,933,345 |
| Mar 2026 | 0 | — | -3,271,952 | -3,195,987 | 23,559,636 | 22,190,231 | 6,119,155 |
| Dec 2025 | 0 | — | -3,559,041 | -3,367,679 | 15,923,198 | 14,438,792 | 7,275,553 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-17,304,395
Investing CF
—
Financing CF
$26,830,641
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-4.25
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-189,781,770
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-13,003,997
Pretax Income TTM
$-13,010,570
Interest Exp TTM
$6,573
Analysts
2
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -20,200,031 | -19,864,902 | 15,923,198 | 7,275,553 | 8,647,645 | -24,594,643 |
| Dec 2024 | 0 | -30,798,889 | -29,918,802 | 15,503,088 | 14,690,516 | 812,572 | -33,543,916 |
| Dec 2023 | 0 | -39,503,636 | -39,260,837 | 23,700,388 | 17,981,672 | 5,718,716 | -28,324,353 |
| Dec 2022 | 0 | -28,228,758 | -28,261,442 | 18,923,675 | 10,529,429 | 8,394,246 | -18,960,581 |
TTM Snapshot
Revenues TTM
$468,085
NetIncome TTM
$-13,022,270
OpCashFlow TTM
—
Assets (Latest)
$21,140,590
Forward EPS
$-0.85
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SILO | Silo Pharma, Inc. | $4.00M | $1.71 | — |
| XTLB | XTL BIOPHARMACEUTICALS LTD | $3.98M | $1.62 | — |
| IMNN | Imunon, Inc. | $3.97M | $0.61 | — |
| KPRX | KIORA PHARMACEUTICALS INC | $4.11M | $0.93 | — |
| TCRT | Alaunos Therapeutics, Inc. | $4.22M | $1.66 | — |
News headlines (Yahoo Finance, 1h cache)
Reviva Pharmaceuticals to Present at the Life Sciences Investor Forum on June 24th
2026-06-23 12:00 · Yahoo
Reviva to Participate in a Fireside Chat Hosted by A.G.P. on Brilaroxazine’s Potential Across Multiple Neuropsychiatric Indications
2026-04-23 12:00 · Yahoo
RVPH: First Quarter 2026 Results
2026-05-27 10:55 · Yahoo
Reviva Announces Letter to Shareholders
2026-04-15 12:00 · Yahoo
Reviva Reports Full Year 2025 Financial Results and Recent Business Highlights
2026-03-30 10:05 · Yahoo
RVPH: Shareholder Letter Introduces New IP
2026-04-20 09:30 · Yahoo
RVPH: Cleared for Takeoff – 2Q:26 Initiation of RECOVER 2
2026-04-01 12:35 · Yahoo
Maxim Turns Cautious on Reviva Pharmaceuticals Holdings, Inc. (RVPH) Despite Phase 3 Progress Plans
2026-04-21 02:46 · Yahoo
Reviva Reports First Quarter 2026 Financial Results and Recent Business Highlights
2026-05-13 20:35 · Yahoo
Reviva Reports Second Quarter 2026 Financial Results and Recent Business Highlights
2026-08-12 20:29 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.